Assessment of genetically modified maize DP915635 for food and feed uses, under regulation (EC) No 1829/2003 (application EFSA‐GMO‐NL‐2020‐172)

Abstract

Genetically modified maize DP915635 was developed to confer tolerance to glufosinate herbicide and resistance to corn rootworm pests. These properties were achieved by introducing the ipd079Ea, mo‐pat and pmi expression cassettes. The molecular characterisation data and bioinformatic analyses do not identify issues requiring food/feed safety assessment. None of the identified differences in the agronomic/phenotypic and compositional characteristics tested between maize DP915635 and its conventional counterpart needs further assessment, except for the levels of crude protein in forage, which does not raise nutritional and safety concerns. The GMO Panel does not identify safety concerns regarding the toxicity and allergenicity of the IPD079Ea, PAT and PMI proteins expressed in maize DP915635. The GMO Panel finds no evidence that the genetic modification impacts the overall safety of maize DP915635. In the context of this application, the consumption of food and feed from maize DP915635 does not represent a nutritional concern in humans and animals. The GMO Panel concludes that maize DP915635 is as safe as the conventional counterpart and non‐GM maize varieties tested, and no post‐market monitoring of food/feed is considered necessary. In the case of accidental release of viable maize DP915635 grains into the environment, this would not raise environmental safety concerns. The post market environmental monitoring plan and reporting intervals are in line with the intended uses of maize DP915635. The GMO Panel concludes that maize DP915635 is as safe as its conventional counterpart and the tested non‐GM maize varieties with respect to potential effects on human and animal health and the environment.

Assessment of genetically modified maize DP202216 for food and feed uses, under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐NL‐2019‐159)

“…The effects of temperature and pH on PAT protein have been previously evaluated by the GMO Panel (EFSA, 2005 , 2007 ; EFSA GMO Panel, 2018c , 2024a , 2024b ). In relation to the ZMM28 protein, the deduced amino acid sequence as defined by the zmm28 gene introduced in maize DP202216 is identical to the endogenous ZMM28 protein present in the GM plant (see Section 3.3.3.1 ) and no studies were provided by the applicant.…”

“…In vitro protein degradation studies on PAT protein have been previously evaluated by the EFSA GMO Panel (EFSA, 2005 , 2007 ; EFSA GMO Panel, 2018c , 2024a , 2024b ). In relation to the ZMM28 protein, no studies were provided by the applicant.…”

“…The PAT protein was previously assessed by the GMO Panel in the context of other applications (EFSA, 2005 , 2007 ; EFSA GMO Panel, 2018 , 2024a , 2024b ) and no safety concerns for humans and animals (i.e. farmed and companion animals) were identified.…”